SymBio Pharmaceuticals Limited
San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 http://www.symbiosis.co.jp/

24 April 2007

SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director, President and Chief Executive Officer

SymBio Pharmaceuticals Signs Agreement with Astellas Deutschland GmbH: In-Licenses Rights to"Bendamustine" in Key Asia-Pacific Rim Countries

SymBio Pharmaceuticals Limited recently signed a definitive License Agreement with Astellas Deutschland GmbH (Munich, Germany), a subsidiary of Astellas Pharma Inc. (Tokyo, Japan), for exclusive rights to development and commercialization of the antineoplastic agent, SyB L-0501（"bendamustine hydrochloride"）, in China, Korea, Taiwan, and Singapore.

SymBio is currently conducting clinical studies on SyB L-0501, in Non-Hodgkin's Lymphoma patients in Japan. This new Agreement signifies the intention of SymBio Pharmaceuticals and Astellas Deutschland GmbH to further expand SyB L-0501development into other Asia-Pacific Rim countries.

Significant growth in medical needs, and an increasing demand for higher quality therapeutic options, are expected in key Asia-Pacific markets currently undergoing rapid economic development. Further expansion of business activities in addressing these anticipated needs, is one of SymBio's most important strategic initiatives. Hence, SymBio established an Asia-Pacific Office on April 1st, 2007 that reports directly to the President and CEO, and will divert significant resources into building its presence within the region.

SymBio Pharmaceuticals will establish a stronger presence across the Asia-Pacific region with the development and commercialization of SyB L-0501 and SyB‐0701（"AB1001"）, a transdermal patch in-licensed from Abeille Pharmaceuticals Inc. last March, in key Asia-Pacific Rim countries. In line with its ongoing Business Development strategy, SymBio Pharmaceuticals intends to continue placing a high priority on in-licensing rights for Japan and other growing Asian markets.

Similar to the situation existing in Japan, the therapeutic areas of oncology, hematology, and auto-immune disease are emerging as areas of unmet medical needs across the Asia-Pacific region. In pursuit of its corporate mission, SymBio will place significant effort and resources into delivering effective therapies to patients in need across the Asia Pacific region, as rapidly as possible.

【Company Profile】

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals' focus is on oncology/hematology and autoimmune disease therapies. Established in March 2005 by Fuminori Yoshida, who previously served as both Corporate Vice President of Amgen Inc. and president of Amgen Japan, SymBio Pharmaceuticals' underlying corporate philosophy is "delivering hope to patients in need," and the company aims to address unmet medical needs of patients in Japan by cultivating a mutually beneficial or symbiotic relationship among physicians, scientists, regulatory

agencies, and investors. SymBio Pharmaceuticals core philosophy is that profitability and socially responsibility as a pharmaceutical enterprise can go hand in hand, and need not be mutually exclusive.

About Astellas Deutschland GmbH:
Astellas Deutschland GmbH, Munich is a German subsidiary of Astellas Pharma Inc., based in Tokyo, Japan. In April 2005, Astellas Pharma Inc. was created through the merger of Yamanouchi Pharmaceutical Co., Ltd and Fujisawa Pharmaceutical Co., Ltd. The organization is committed to becoming a global pharmaceutical company by combining outstanding R&D and marketing capabilities with international expertise, thereby sustaining a phenomenal growth rate and strong presence within the world pharmaceutical market.

For further information, please contact:
SymBio Pharmaceuticals Limited
Kyoko Seki,
Corporate Officer, Director Public Relations and Investor Relations
Tel: +81 (0) 3 5472 1123
E-mail: kseki@symbiosis.co.jp
URL:http://www.symbiosis.co.jp

（Note）
In December 2005, SymBio entered into a License Agreement with Astellas Pharma GmbH (Munich,Germany) for the exclusive development and distribution of “Bendamustine” for the Japanese market. This anticancer drug has been used extensively in Germany, under the trade name “Ribomustin®,” for the treatment of non-Hodgkin's lymphoma. For Japan, SymBio is now conducting a phase I clinical trial of SyB L-0501 at four facilities, with patients who have relapsed/refractory indolent non-Hodgkin's lymphoma. Enrollment of a total of nine patients was completed earlier than scheduled, and the phase I clinical trial, including data analysis, should be completed by the end of August this year.